Tabalumab

Tabalumab (LY2127399) is a humanised anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus[1].

Research Areas >> Inflammation/Immunology

BAFF[1].

Tabalumab (1-100 ng/mL; 44 h) neutralizes soluble and membrane-bound BaFF both in T1165.17 cells and (1 µg/mL; 3 days) CD19+ B-cells[1]. Tabalumab (50 µg/mL; 15 min) inhibits BaFF binding to BR3, TacI, and BcMa in HEK293 cells[1]. Cell Viability Assay[1] Cell Line: T1165.17 cells Concentration: 1-100 ng/mL Incubation Time: 44 h Result: Neutralizeed tabalumab neutralization of soluble human, cynomolgus monkey, or rabbit BAFF with IC50 values of 104, 143, and 176 pM in T1165.17 cells, respectively. Cell Viability Assay[1] Cell Line: CD19+ B-cells Concentration: 1 µg/mL Incubation Time: 3 days Result: Demonstrated the ability to neutralize the membrane-bound form of BAFF compared with the soluble form of BAFF. Cell Viability Assay[1] Cell Line: HEK293 cells (transfected with either BR3, TACI, or BCMA) Concentration: 50 µg/mL Incubation Time: 15 min (pre-treat) Result: Prevented the binding of BAFF to BR3, TACI, or BCMA on the cell surface.

Tabalumab (500 µg/rat; s.c.; single) leads to decreased B-cells and a reduction in non-canonical nF-κB signaling[1]. Animal Model: Human BAFF Tg mice[1]. Dosage: 500 µg/rat Administration: Subcutaneous injection, single. Result: Significantly decreased the splenic B-cell count between day 4 and 8. Decreased levels of p52, which returned to near the BAFF Tg level at Day 23.

[1]. Manetta J, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014 Aug 20;7:121-31.